94 results
8-K
EX-99.2
INMB
INmune Bio Inc
10 May 24
INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a
7:46pm
completed the first dosing. Following review by the Safety Review Committee (SRC), approval was granted to proceed with the second dose level (cohort 2 … ) and two patients have been enrolled. The first patient of the middle dose cohort is expected to be treated this month.
Safety of INKmune remains on track
8-K
EX-99.1
INMB
INmune Bio Inc
30 Apr 24
Other Events
4:01pm
(mCRPC). The Company is pleased to announce the successful completion of the first cohort in the trial. Following review by the Safety Review Committee … without the need for conditioning therapy, pre-medication, or cytokine support.
“We are pleased with the safety of INKmune in men with mCRPC
8-K
EX-10.1
INMB
INmune Bio Inc
26 Apr 24
INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:28pm
, including without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational health and safety … , product quality and safety and employment and labor matters, except in each case of (i), (ii) and (iii) as could not have or reasonably be expected
424B5
1rr6j0b
26 Apr 24
Prospectus supplement for primary offering
4:26pm
8-K
EX-10.1
2dcx75v 5j3o7
22 Apr 24
Entry into a Material Definitive Agreement
5:10pm
424B5
zp8emb906oj wdjm
22 Apr 24
Prospectus supplement for primary offering
5:09pm
8-K
EX-99.1
g0a56y1 yvpwfbmd8w
29 Mar 24
INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update
4:01pm
8-K
EX-99.1
3ywt5nhnau1y iz
2 Jan 24
INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune™ in Patients with Metastatic Castration-Resistant Prostate Cancer
4:00pm
8-K
EX-99.2
i293s
31 Oct 23
Regulation FD Disclosure
4:25pm
424B5
sq19h8gldkyya29rs
16 Aug 23
Prospectus supplement for primary offering
4:39pm
8-K
EX-99.2
juora59mwllpcj6 3f
12 Jul 23
Other Events
12:00am
8-K
EX-99.1
5r8gv0b
12 May 23
HARNESSING THE POWER OF THE INNATE IMMUNE SYSTEM INMB Webinar Phase I/II Trial of INKmune ʳ in Metastatic Castration - Resistant Prostate Cancer
8:00am
8-K
EX-99.1
vfm8u6zvdvuzu2rdvw7l
8 May 23
Other Events
8:02am
8-K
EX-99.1
7gx is8nblrz1mnu
3 Apr 23
Other Events
9:12am